Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Olivia Coiculescu

Neurology New London, CT Medical Doctor

NPI 1639338858 CMS profile 1263207

194 Howard St, New London, CT 06320

Open in the dashboard

General payments

$1,124

45 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Olivia Coiculescu of New London, CT is reported in the CMS Open Payments database as having received $1,124 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $238 9
2022 General $622 24
2021 General $154 7
2019 General $110 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olivia Coiculescu
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Olivia Coiculescu were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Olivia Coiculescu Neurology median Middle half National median
2019 $110 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $154 $438 $104–$2,547 $132
2022 $622 $442 $103–$2,388 $149
2023 $238 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $915 35 payments
  2. Allergan Inc. $64 4 payments
  3. Amgen Inc. $50 1 payment
  4. SK Life Science, Inc. $28 1 payment
  5. Collegium Pharmaceutical, Inc. $22 1 payment
  6. LivaNova USA, Inc. $19 1 payment
  7. Biogen, Inc. $13 1 payment
  8. Promius Pharma LLC $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,111 44 payments
  2. Education $13 1 payment
Products named General payments · program years 2019–2023
  1. UBRELVY $752 28 payments
  2. BOTOX Hyperhydrosis $94 5 payments
  3. BOTOX Botox Therapeutic $76 3 payments
  4. AIMOVIG $50 1 payment
  5. QULIPTA $38 2 payments
  6. ELYXYB - celecoxib $22 1 payment
  7. BOTOX Facial Aesthetics $21 1 payment
  8. VNS Therapy $19 1 payment
  9. TYSABRI $13 1 payment
  10. ZEMBRACE SYMTOUCH $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

4,244

Median for Neurology: 833

Drug cost

$413,488

Median for Neurology: $202,670

Branded share of claims

21.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 64 $94,276
Qulipta Atogepant Brand 36 $44,821
Aptiom Eslicarbazepine Acetate Brand 18 $34,386
Aimovig Autoinjector Erenumab-Aooe Brand 21 $31,195
Topamax Topiramate Brand 11 $28,242
Emgality Pen Galcanezumab-Gnlm Brand 27 $19,973
Levetiracetam Generic 551 $17,178
Ubrelvy Ubrogepant Brand 13 $14,263
Tiagabine Hcl Generic 12 $11,621
Gabapentin Generic 490 $9,563

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$104,489

Of which drugs: $42,780

Medicare patients

413

Average age 71

Services billed

9,292

238 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 49%
Depression 37%
Diabetes 31%
Chronic kidney disease 24%
Ischemic heart disease 23%
Atrial fibrillation 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 14 8,600 $42,780

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record